Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 3/2020

26.03.2020 | Review

Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors

verfasst von: B. Mahalakshmi, Rathinasamy Baskaran, M. Shanmugavadivu, Ngoc Tuan Nguyen, Bharath Kumar Velmurugan

Erschienen in: Cellular Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Insulinoma-associated protein 1 (INSM1), a transcriptional regulator with a zinc-finger DNA-binding domain, has been validated as a cytoplasmic marker for neuroendocrine differentiation of tumor cells. Next to its abundant expression in the fetal pancreas, it is expressed in brain tumors, pheochromocytomas, medullary thyroid carcinomas, insulinomas and pituitary and small-cell lung carcinomas. INSM1 is not expressed in normal adult tissues and/or most non-neuroendocrine tumors. It regulates various downstream signaling pathways, including the Sonic Hedgehog, PI3K/AKT, MEK/ERK1/2, ADK, p53, Wnt, histone acetylation, LSD1, cyclin D1, Ascl1 and N-Myc pathways. Although INSM1 appears to be a subtle and specific biomarker for neuroendocrine tumors, its role in tumor development has remained unclear.

Conclusions

Here, we highlight INSMI expression, as well as its diagnostic significance and use as a therapeutic target in various neuroendocrine tumors. Targeting signaling pathways or gene expression alterations associated with INSM1 expression may be instrumental for the design of novel therapeutic strategies for neuroendocrine tumors.
Literatur
1.
E.F. Rodriguez, J.J. Fite, S. Chowsilpa, Z. Maleki, Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience. Hum. Pathol. 85, 128–135 (2019)PubMed
2.
Y. Goto, M.G. Desilva, A. Toscani, B.S. Prabhakar, A.L. Notkins, M.S. Lan, A novel human insulinoma-associated cDNA, Ia-1, encodes a protein with zinc-finger DNA-binding motifs. J. Biol. Chem. 267, 15252–15257 (1992)PubMed
3.
W.D. Liu, H.W. Wang, M. Muguira, M.B. Breslin, M.S. Lan, INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases. Biochem. J. 397, 169–177 (2006)
4.
M.B. Breslin, M. Zhu, A.L. Notkins, M.S. Lan, Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. Nucleic Acids Res. 30, 1038–1045 (2002)PubMedPubMedCentral
5.
M.S. Gierl, N. Karoulias, H. Wende, M. StrehleC, Birchmeier, The Zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. Genes Dev. 20, 2465–2478 (2006)PubMedPubMedCentral
6.
S.Q. Jia, A. Ivanov, D. Blasevic, T. Muller, B. Purfurst, W. Sun, W. Chen, M.N. Poy, N. Rajewsky, C. Birchmeier, Insm1 cooperates with Neurod1 and Foxa2 to maintain mature pancreatic beta-cell function. EMBO J. 34, 1417–1433 (2015)
7.
A.B. Osipovich, Q.M. Long, E. Manduchi, R. Gangula, S.B. Hipkens, J. Schneider, T. Okubo, C.J. Stoeckert, S. Takada, M.A. Magnuson, Insm1 promotes endocrine cell differentiation by modulating the expression of a network of genes that includes Neurog3 and Ripply3. Development 141, 2939–2949 (2014)PubMedPubMedCentral
8.
J.E. Welcker, L.R. Hernandez-Miranda, F.E. Paul, S.Q. Jia, A. Ivanov, M. SelbachC, Birchmeier, Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors. Development 140, 4947–4958 (2013)PubMed
9.
H. Wildner, M.S. Gierl, M. Strehle, P. PlaC, Birchmeier, Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympathoadrenal lineage. Development 135, 473–481 (2008)PubMed
10.
M.S. Lan, Q. Li, J. Lu, W.S. Modi, A.L. Notkins, Genomic organization, 5'-upstream sequence, and chromosomal localization of an insulinoma-associated intronless gene, IA-1. J. Biol. Chem. 269, 14170–14174 (1994)PubMed
11.
Q. Li, A.L. Notkins, M.S. Lan, Molecular characterization of the promoter region of a neuroendocrine tumor marker, IA-1. Biochem. Biophys. Res. Commun. 236, 776–781 (1997)PubMed
12.
M.S. Lan, M.B. Breslin, Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEBJ 23, 2024–2033 (2009)
13.
N. Pedersen, M.W. Pedersen, M.S. Lan, M.B. Breslin, H.S. Poulsen, The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther. 13, 375–384 (2006)PubMed
14.
E. De Smaele, C. Fragomeli, E. Ferretti, M. Pelloni, A. Po, G. Canettieri, S. Coni, L. Di Marcotullio, A. Greco, M. Moretti, C. Di Rocco, S. Pazzaglia, M. Maroder, I. Screpanti, G. GianniniA, Gulino, An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia 10, 89–98 (2008)PubMedPubMedCentral
15.
M.T. Lilo, Y. Chen, R.E. LeBlanc, INSM1 is more sensitive and interpretable than conventional immunohistochemical stains used to diagnose Merkel cell carcinoma. Am. J. Surg. Pathol. 42, 1541–1548 (2018)PubMed
16.
H.W. Wang, M.B. Breslin, C.C. Chen, V. Akerstrom, Q. Zhong, M.S. Lan, INSM1 promoter-driven adenoviral Herpes Simplex Virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors. Hum. Gene Ther. 20, 1308–1318 (2009)PubMedPubMedCentral
17.
T. Zhang, C. Chen, M.B. Breslin, K. Song, M.S. Lan, Extra-nuclear activity of INSM1 transcription factor enhances insulin receptor signaling pathway and Nkx6.1 expression through RACK1 interaction. Cell. Signal. 26, 740–747 (2014)PubMedPubMedCentral
18.
T. Zhang, W.D. Liu, N.A. Saunee, M.B. Breslin, M.S. Lan, Zinc Finger transcription factor INSM1 interrupts Cyclin D1 and CDK4 binding and induces cell cycle arrest. J. Biol. Chem. 284, 5574–5581 (2009)PubMedPubMedCentral
19.
M.B. Breslin, M. Zhu, M.S. Lan, NeuroD1/E47 regulates the e-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system. J. Biol. Chem. 278, 38991–38997 (2003)PubMedPubMedCentral
20.
G. Mellitzer, S. Bonne, R.F. Luco, M. Van de Casteele, N. Lenne-Samuel, P. Collombat, A. Mansouri, J. Lee, M. Lan, D. Pipeleers, F.C. Nielsen, J. Ferrer, G. GradwohlH, Heimberg, IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas. EMBO J. 25, 1344–1352 (2006)PubMedPubMedCentral
21.
M.B. Breslin, H.W. Wang, A. Pierce, R. Aucoin, M.S. Lan, Neurogenin 3 recruits CBP co-activator to facilitate histone H3/H4 acetylation in the target gene INSM1. FEBS Lett. 581, 949–954 (2007)PubMedPubMedCentral
22.
J.E. Welcker, L.R. Hernandez-Miranda, F.E. Paul, S. Jia, A. Ivanov, M. SelbachC, Birchmeier, Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors. Development 140, 4947–4958 (2013)PubMed
23.
S.Q. Jia, H. Wildner, C. Birchmeier, Insm1 controls the differentiation of pulmonary neuroendocrine cells by repressing Hes1. Dev. Biol. 408, 90–98 (2015)PubMed
24.
W.H. Tao, Y. Zhang, L.J. Ma, C.J. Deng, H.L. Duan, X.H. Liang, R. Liao, S.Q. Lin, T. Nie, W.Q. Chen, C.C. Wang, C. Birchmeier, S.Q. Jia, Haploinsufficiency of INSM1 impairs postnatal baseline beta-cell mass. Diabetes 67, 2615–2625 (2018)PubMed
25.
C.C. Chen, M.B. Breslin, M.S. Lan, INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget 6, 36700–36712 (2015)PubMedPubMedCentral
26.
G. Mellitzer, S. Bonne, R.F. Luco, M. Van De Casteele, N. Lenne-Samuel, P. Collombat, A. Mansouri, J. Lee, M. Lan, D. Pipeleers, F.C. Nielsen, J. Ferrer, G. GradwohlH, Heimberg, IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas. EMBO J. 25, 1344–1352 (2006)PubMedPubMedCentral
27.
J. Xie, T. Cai, H. Zhang, M.S. Lan, A.L. Notkins, The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. Genomics 80, 54–61 (2002)PubMedPubMedCentral
28.
A. Duggan, T. Madathany, S.C. de Castro, D. Gerrelli, K. GuddatiJ, Garcia-Anoveros, Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis. J. Comp. Neurol. 507, 1497–1520 (2008)PubMed
29.
L.M. Farkas, C. Haffner, T. Giger, P. Khaitovich, K. Nowick, C. Birchmeier, S. Paabo, W.B. Huttner, Insulinoma-associated 1 has a panneurogenic role and promotes the generation and expansion of basal progenitors in the developing mouse neocortex. Neuron 60, 40–55 (2008)PubMed
30.
H. Wildner, M.S. Gierl, M. Strehle, P. Pla, C. Birchmeier, Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage. Development 135, 473–481 (2008)PubMed
31.
B. Oronsky, P.C. Ma, D. Morgensztern, C.A. Carter, Nothing But NET: A review of neuroendocrine tumors and carcinomas. Neoplasia 19, 991–1002 (2017)PubMedPubMedCentral
32.
P.S. Rush, J.N. Rosenbaum, M. Roy, R.M. Baus, D.D. Bennett, R.V. Lloyd, Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). J. Cutan. Pathol. 45, 129–135 (2018)PubMed
33.
Y. Takase, Y. Naito, Y. Okabe, Y. Ishida, T. Yamaguchi, H. Abe, K. Murata, T. Ito, M. Tanigawa, A. Kawahara, H. YanoJ, Akiba, Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients. Cytopathology 30, 194–200 (2019)PubMed
34.
S. Mukhopadhyay, J.K. Dermawan, C.P. Lanigan, C.F. Farver, Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod. Pathol. 32, 100–109 (2019)PubMed
35.
A. Yoshida, N. Makise, S. Wakai, A. Kawai, N. Hiraoka, INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. Mod. Pathol. 31, 744–752 (2018)PubMed
36.
M. Tanigawa, M. Nakayama, T. Taira, S. Hattori, Y. Mihara, R. Kondo, H. Kusano, K. Nakamura, Y. Abe, Y. Ishida, Y. Okabe, T. Hisaka, K. Okuda, K. Fujino, T. Ito, A. Kawahara, Y. Naito, R. Yamaguchi, J. Akiba, Y. AkagiH, Yano, Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med. Mol. Morphol. 51, 32–40 (2018)PubMed
37.
L.M. Rooper, R. Sharma, Q.K. Li, P.B. Illei, W.H. Westra, INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am. J. Surg. Pathol. 41, 1561–1569 (2017)PubMed
38.
J.N. Rosenbaum, Z.Y. Guo, R.M. Baus, H. Werner, W.M. Rehrauer, R.V. Lloyd, INSM1A anovel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am. J. Clin. Pathol. 144, 579–591 (2015)PubMed
43.
C. Chen, A.L. Notkins, M.S. Lan, Insulinoma-associated-1: From neuroendocrine tumor marker to cancer therapeutics. Mol. Cancer Res. 17, 1597–1604 (2019)PubMed
44.
C. Chen, M.B. Breslin, M.S. Lan, INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget 6, 36700–36712 (2015)PubMedPubMedCentral
45.
S. Kobayashi, T. Contractor, E. Vosburgh, Y.C.N. Du, L.H. Tang, R. Clausen, C.R. Harris, Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis 8, 1–16 (2019)
40.
H. Kajiwara, K. Hirabayashi, M. Miyazawa, N. Nakamura, T. Hirasawa, T. Muramatsu, M. Mikami, M. Yasuda, R.Y. Osamura, Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. Arch. Gynecol. Obstet. 279, 521–525 (2009)PubMed
46.
M. Petrovic, Z. Bukumiric, V. Zdravkovic, S. Mitrovic, H.D. AtkinsonV, Jurisic, The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med. Oncol. 31, 823 (2014)PubMed
47.
M.S. Lan, E.K. Russell, J. Lu, B.E. Johnson, A.L. Notkins, Ia-1, a new marker for neuroendocrine differentiation in human lung-cancer cell-lines. Cancer Res. 53, 4169–4171 (1993)PubMed
48.
E.F. Rodriguez, S. Chowsilpa, Z. Maleki, Insulinoma-sssociated protein 1 immunostain: A diagnostic tool for pulmonary small cell carcinoma in cytology. Acta Cytol. 62, 333–338 (2018)PubMed
49.
M. Wolf, R. Holle, K. Hans, P. Drings, K. Havemann, Analysis of prognostic factors in 766 patients with small-cell lung-cancer (Sclc) - the role of sex as a predictor for survival. Br. J. Cancer 63, 986–992 (1991)PubMedPubMedCentral
39.
C.C. Chen, M.B. Breslin, M.S. Lan, Ectopic expression of a small cell lung cancer transcription factor, INSM1 impairs alveologenesis in lung development. BMC Pulm. Med. 16, 49 (2016)PubMedPubMedCentral
50.
K. Fujino, Y. Motooka, W.A. Hassan, M.O.A. Abdalla, Y. Sato, S. Kudoh, K. Hasegawa, K. Niimori-Kita, H. Kobayashi, I. Kubota, J. Wakimoto, M. Suzuki, T. Ito, Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am. J. Pathol. 185, 3164–3177 (2015)PubMed
51.
E.E. Doxtader, S. Mukhopadhyay, Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. Cancer Cytopathol. 126, 243–252 (2018)PubMed
52.
O. Farouk, M.A. Ebrahim, A. Senbel, Z. Emarah, W. Abozeed, M.O. Seisa, S. Mackisack, S.A. Jalil, S. Abdelhady, Breast cancer characteristics in very young Egyptian women <= 35 years. Breast Cancer Target 8, 53–58 (2016)
53.
M.J. Duffy, Serum tumor markers in breast cancer: Are they of clinical value? Clin. Chem. 52, 345–351 (2006)PubMed
54.
L.E. Rosen, P. Gattuso, Neuroendocrine tumors of the breast. Arch. Pathol. Lab. Med. 141, 1577–1581 (2017)PubMed
55.
K.A. Egland, J.J. Vincent, R. Strausberg, B. Lee, I. Pastan, Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc. Natl. Acad. Sci. U. S. A. 100, 1099–1104 (2003)PubMedPubMedCentral
56.
N. Bretschneider, H. Brand, N. Miller, A.J. Lowery, M.J. Kerin, F. Gannon, S. Denger, Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner. Cancer Res. 68, 106–114 (2008)PubMed
57.
C. Gillett, P. Smith, W. Gregory, M. Richards, R. Millis, G. Peters, D. Barnes, Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 69, 92–99 (1996)PubMed
58.
B. Zengel, E. Vardar, S. Demir, A. Alacacioglu, H. Postaci, A.G. Denecli, M. Sakizli, Beta-catenin stability, frizzled and cyclin D1 proteins expression in human breast cancer and its relation with their prognosis. EJC Suppl. 7, 288–288 (2009)
59.
B. Zengel, E. Vardar, H. Postaci, S. Kececiler, A. Alacacioglu, A.G. Denecli, M. Sakizli, beta-Catenin Stability, Cyclin D1 and Frizzled proteins expression in human breast cancer and their relation with the prognosis. Turk. Klin. Tip. Bilim. 31, 350–357 (2011)
60.
M. Roy, D.G. Buehler, R.R. Zhang, M.L. Schwalbe, R.M. Baus, M.S. Salamat, R.V. Lloyd, J.N. Rosenbaum, Expression of insulinoma-associated protein 1 (INSM1) and orthopedia homeobox (OTP) in tumors with neuroendocrine differentiation at rare sites. Endocr. Pathol. 30, 35–42 (2019)PubMed
61.
R. Nadal, M. Schweizer, O.N. Kryvenko, J.I. Epstein, M.A. Eisenberger, Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213–219 (2014)PubMedPubMedCentral
62.
W. Wang, J.I. Epstein, Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 32, 65–71 (2008)PubMed
63.
Z.X. Xin, Y. Zhang, Z. Jiang, L. Zhao, L.C. Fan, Y.Q. Wang, S.W. Xie, S.G. Xun, Y.J. Zhu, J.H. Pan, Q. Liu, Y.R. Huang, B.J. Dong, W. Xue, Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum. Pathol. 79, 151–159 (2018)PubMed
64.
S. Uccella, G. Ottini, C. Facco, R. Maragliano, S. Asioli, F. Sessa, S. La Rosa, Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis and classification. Pathologica 109, 14–30 (2017)PubMed
65.
C.B. Tempfer, I. Tischoff, A. Dogan, Z. Hilal, B. Schultheis, P. Kern, G.A. Rezniczek, Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC Cancer 18, 530 (2018)PubMedPubMedCentral
41.
S. Kuji, R. Watanabe, Y. Sato, T. Iwata, Y. Hirashima, M. Takekuma, I. Ito, M. Abe, R. Nagashio, K. Omae, D. Aoki, T. Kameya, A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. Gynecol. Oncol. 144, 384–390 (2017)PubMed
66.
K. Kriegsmann, C. Zgorzelski, D. Kazdal, M. Cremer, T. Muley, H. Winter, R. Longuespee, J. Kriegsmann, A. Warth, M. Kriegsmann, Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl. Immunohistochem. Mol. Morphol. 32, 100–109 (2018)
67.
M. Svajdler, R. Mezencev, B. Saskova, O. Ondic, P. Mukensnabl, M. Michal, Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens. Hum. Pathol. 85, 58–64 (2019)PubMed
68.
C. Leblebii, B.B. Sigirci, C.K. Talu, S.B. Koca, G.E. Huq, CD10, TDAG51, CK20, AR, INSM1, and Nestin expression in the differential diagnosis of trichoblastoma and basal cell carcinoma. Int. J. Surg. Pathol. 27, 19–27 (2019)
42.
A.W.S. Tseng, C.C. Chen, M.B. Breslin, M.S. Lan, Tumor-specific promoter-driven adenoviral therapy for insulinoma. Cell. Oncol. 39, 279–286 (2016)
69.
V. Akerstrom, C. Chen, M.S. Lan, M.B. Breslin, Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas. Cancer Gene Ther. 19, 828–838 (2012)PubMed
70.
S.R. Michaelsen, C.L. Christensen, M. Sehested, F. Cramer, T.T. Poulsen, A.V. Patterson, H.S. Poulsen, Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. J. Gene Med. 14, 445–458 (2012)PubMed
71.
F. Cramer, C.L. Christensen, T.T. Poulsen, M.A. Badding, D.A. Dean, H.S. Poulsen, Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines. Cancer Gene Ther. 19, 675–683 (2012)PubMed
72.
73.
C.C. Chen, M.B. Breslin, M.S. Lan, Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer. Cell. Signal. 46, 83–91 (2018)PubMed
74.
C.C. Chen, M.B. Breslin, J.J. Guidry, M.S. Lan, 5-Iodotubercidin represses insulinoma-associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth. J. Biol. Chem. 294, 5456–5465 (2019)PubMedPubMedCentral
Metadaten
Titel
Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors
verfasst von
B. Mahalakshmi
Rathinasamy Baskaran
M. Shanmugavadivu
Ngoc Tuan Nguyen
Bharath Kumar Velmurugan
Publikationsdatum
26.03.2020
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 3/2020
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00505-9

Weitere Artikel der Ausgabe 3/2020

Cellular Oncology 3/2020 Zur Ausgabe

Original paper

WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway

Original paper

FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer

Short Communication

Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients

OriginalPaper

Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

Original paper

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer

Original paper

CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Open Access 22.02.2024 | Pathologie | Originalien

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien
Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien
Automatische Quantifizierung von Leberverfettung